Global Gastroesophageal reflux disease Market
Gastroesophageal reflux disease, GERD is a common condition in which the stomach contents move up into the esophagus. Reflux becomes a disease when it causes frequent or severe symptoms or injury. Reflux may damage the esophagus, pharynx or respiratory tract.
You may feel a burning in the chest or throat known as heartburn. Sometimes, you can taste stomach fluid in the back of the mouth. If you have these symptoms more than twice a week, you may have GERD. You can also have GERD without having heartburn.
People with asthma are at increased risk of developing GERD. During an asthma attack, the lower esophageal sphincter relaxes, and stomach contents can flow back, or reflux, into the esophagus. Some medications for asthma, particularly theophylline, can exacerbate reflux symptoms.
Conditions that predispose to GERD include the following:
Obesity.
A hiatal hernia, where the top of the stomach bulges up above the diaphragm.
Pregnancy.
Connective tissue disorders, such as scleroderma.
Delayed stomach emptying.
Symptoms
Heartburn, a burning feeling in the chest
Regurgitation of sour or bitter liquid
Non-burning chest pain
Difficulty swallowing
Coughing
Shortness of breath
Hoarseness or change in voice
Sore throat
Feeling a lump in the throat
Market Segmentation
Diagnostic Methods
Upper Endoscopy
Standard Endoscopy: A procedure where a flexible tube with a camera examines the esophagus and stomach for inflammation or other issues.
Capsule Endoscopy: Involves swallowing a small capsule that captures images of the gastrointestinal tract.
Ambulatory Acid (pH) Probe Test
Ambulatory Acid (pH) Probe Test
Catheter-based Monitoring: A thin tube is passed through the nose down the esophagus in which the acid level is monitored from 24 to 96 hours.
Wireless pH Monitoring
The device is placed endoscopically at a distance of 5 cm above the lower esophageal sphincter, and continuous monitoring for esophageal acid exposure goes on.
Esophageal Manometry
High-resolution Manometry: Tests that evaluate coordinated muscle movement (motility) of the esophagus.
Traditional Manometry: Measures the function of these muscles in contraction and relaxation to keep stomach acid from flowing back into the esophagus.
Treatments
Medications
PPIs: Reduce your stomach's secretion of acid.
H2 receptor blockers: reduces the production of acid in your stomach
Antacids: over-the-counter drugs that are used to counteract the acids in the stomach.
Surgical Treatments
Fundoplication: It tightens the valve at the base of the lower esophagus, preventing acids from refluxing back into it.
Transoral Incisionless Fundoplication (TIF): This is an endoscopic approach taken through the mouth.
LINX device: Inhibits contents from the stomach to backflow up into the esophagus.
Geographical Segmentation
North America
United States
Canada
Europe
Germany
United Kingdom
France
Asia-Pacific
China
Japan
India
List of Market Players
GlaxoSmithKline PLC
SRS Life Sciences
Johnson & Johnson Services Inc.
Takeda Pharmaceutical Company Limited
AstraZeneca PLC
Reckitt Benckiser Group PLC
Eisai Co. Ltd.
Pfizer Inc.
Medtronic PLC
Teva Pharmaceuticals
HK inno.N Corporation
Sebela Pharmaceuticals
Mylan N.V.
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Ltd.
Drivers
Rising epidemiology of the disease: the prevalent cases of GERD are growing at 77.53% from 441.57 million.
due to lifestyle shift: Gastroesophageal reflux disease affects up to 30% of adults in the Western populations, and the rate is on rise. GERD is associated with lifestyle factors like obesity and smoking tobacco.
Aging populations: GERD is a particularly common disorder in the elderly population.
Esophageal peristalsis may decrease, and esophageal acid exposure and anatomical disruption of the esophagogastric junction may increase with aging.
Rising obesity rates: A total of 2,356,548 patients were included in the obesity and non-obesity groups after propensity score matching.
Obesity appears to be involved not only in the development of GERD symptoms but, also in the occurrence of GERD complication such as erosive esophagitis, Barrett's esophagus and esophageal adenocarcinoma. Obesity was associated with a higher prevalence of GERD and GERD-related complications.
The rise toward modern living standards, accompanied by lifestyle changes and a more hectic pace of life, has been associated with an increasing prevalence of symptomatic GERD in China, reaching 3.8% in 2016. The global prevalence of GERD has been reported to be 13.98%.
Technological advancements: Various types of endoscopic therapies have been established for the management of GERD. The following are the two currently available endoluminal therapies: magnetic sphincter augmentation (MSA) and transoral incision-less fundoplication using the EsophyX (EndoGastric Solutions, Redmond, WA, United States).
Restraints
There are challenges concerning treatment approaches with new diagnostic methods for GERD that are more reliable, safer, and also more comfortable as compared to older methods. PPIs are still the first-line treatment; however, the long-term use of these agents is associated with side effects and loss of effectiveness in some patients. Surgical options, including magnetic sphincter augmentation and laparoscopic fundoplication, are reserved for patients with severe or refractory GERD. The high cost, potential complications, and less accessibility of such procedures also acts as a hindrance to its wide usage and thereby poses as a restraint for the growth of the Global Gastro Esophageal Reflux Disease Market.
Cost-effectiveness of GERD treatment, Proton pump inhibitors (PPIs) seem to be the solution for the non-refractory patients. However, with the introduction of the new drug vonoprazan, it might be displaced due to the former's superiority and cost-effectiveness.
Patients who are severely suffering from GERD and who fail the initial management strategies from lifestyle changes and pharmacological interventions could, therefore, be considered for interventions like laparoscopic fundoplication or magnetic sphincter augmentation.
Global Gastro Esophageal Reflux Disease Market harbours new innovation in the form of nanoparticles (NPs), which promises a treatment revolution. NPs improve drug stability, extend the drug release, as well as shield medication from degradation in the tumbling pungency of gastric juices. Importantly, NPs facilitate targeted delivery of drugs to the affected area in the esophagus for the sustained localized treatment of GERD patients. The control exerted over drug release profiles will help improve the therapeutic outcomes without adverse effects. Furthermore, functionalization of NPs by adding targeting ligands or surface modification will enhance the interaction of the NPs with the inflamed tissues of the esophagus and enhance treatment efficacy. With advanced research and developments in nanomedicine, the use of NPs in GERD care is a significant future development for pharmaceutical innovations that will provide a mainstream platform for more efficient and patient-friendly treatment options.
Developments in diagnostic and screening technologies are transforming the Global Gastro Esophageal Reflux Disease Market, making it possible for less invasive approaches and better prognosis of patients. These developments improve early detection, fine-tune treatment plans, and open up more spaces in the expansion of the market.
Trends
Minimally invasive surgery is becoming more popular, with Transoral Incisionless Fundoplication at the forefront of GERD treatments, providing considerable relief to the millions suffering from chronic acid reflux. This revolutionary, less-invasive procedure offers effective treatment with the EsophyX device without the need for external incisions, setting a new standard in the care of reflux disease.
Drug development has been concentrated on potent histamine type 2 receptor antagonist's, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the above compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.
Advancements in diagnostic and screening technologies are transforming the GERD treatment model, enabling less invasive approaches and enhancing patient outcomes.
